Glucose-Stimulated Insulin Response of Silicon Nanopore-Immunoprotected Islets under Convective Transport
Source abstract
Abstract
Major clinical challenges associated with islet transplantation for type 1 diabetes include shortage of donor organs, poor engraftment due to ischemia, and need for immunosuppressive medications. Semipermeable membrane capsules can immunoprotect transplanted islets by blocking passage of the host's immune components while providing exchange of glucose, insulin, and other small molecules. However, capsules-based diffusive transport often exacerbates ischemic injury to islets by reducing the rate of oxygen and nutrient transport. We previously reported the efficacy of a newly developed semipermeable ultrafiltration membrane, the silicon nanopore membrane (SNM) under convective-driven transport, in limiting the passage of pro-inflammatory cytokines while overcoming the mass transfer limitations associated with diffusion through nanometer-scale pores. In this study, we report that SNM-encapsulated mouse islets perfused in culture solution under convection outperformed those under diffusive conditions in terms of magnitude (1.49-fold increase in stimulation index and 3.86-fold decrease in shutdown index) and rate of insulin secretion (1.19-fold increase and 6.45-fold decrease during high and low glucose challenges), respectively. Moreover, SNM-encapsulated mouse islets under convection demonstrated rapid glucose-insulin sensing within a physiologically relevant time-scale while retaining healthy islet viability even under cytokine exposure. We conclude that encapsulation of islets with SNM under convection improves islet in vitro functionality. This approach may provide a novel strategy for islet transplantation in the clinical setting.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · Diabetes Management and Research · Diabetes and associated disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering and Therapeutic Sciences, University of California−San Francisco, San Francisco, California 94158, United States
Department of Surgery, University of California−San Francisco, San Francisco, California 94143, United States
Funding
University of California, San Francisco · Juvenile Diabetes Research Foundation · National Science Foundation · Rogers Family Foundation
References (40)
Show source-provided references
1. 10.1056/NEJM20000727343040110.1056/NEJM200007273430401 ↗
2. 10.1097/MOT.0b013e32833552d210.1097/MOT.0b013e32833552d2 ↗
3. 10.2337/diacare.26.12.328810.2337/diacare.26.12.3288 ↗
4. 10.1097/01.SLA.0000072110.93780.5210.1097/01.SLA.0000072110.93780.52 ↗
5. 10.1002/bit.2589510.1002/bit.25895 ↗
6. 10.1126/science.146.3643.52410.1126/science.146.3643.524 ↗
7. 10.1016/0963-6897(95)00025-S10.1016/0963-6897(95)00025-S ↗
8. Iwata H. · Transpl. Proc. · 1995 · 27 · 3224
9. 10.1007/s00125-002-1017-010.1007/s00125-002-1017-0 ↗
10. 10.1038/srep2367910.1038/srep23679 ↗
11. 10.1002/aic.69033090210.1002/aic.690330902 ↗
12. 10.1021/jp303855d10.1021/jp303855d ↗
13. 10.1007/s10404-008-0300-x10.1007/s10404-008-0300-x ↗
14. 10.1016/j.cplett.2008.05.00310.1016/j.cplett.2008.05.003 ↗
15. 10.1002/elps.20160015810.1002/elps.201600158 ↗
16. 10.1073/pnas.140221611110.1073/pnas.1402216111 ↗
17. 10.2337/diabetes.42.1.1210.2337/diabetes.42.1.12 ↗
18. 10.1210/en.2011-149910.1210/en.2011-1499 ↗
19. 10.1111/j.1464-5491.2008.02413.x10.1111/j.1464-5491.2008.02413.x ↗
20. 10.2337/dc11-157910.2337/dc11-1579 ↗
21. Maher, J. F.Replacement of Renal Function by Dialysis: A Text Book of Dialysis.Springer Science & Business Media:Berlin, 1989; p1188.10.1007/978-94-009-1087-4 ↗
22. Sircar, S.Principles of Medical Physiology;Thieme:Stuttgart, Germany, 2008; p793.
23. Hedeskov C. J. · Physiol Rev. · 1980 · 60 · 44210.1152/physrev.1980.60.2.442 ↗
24. Rorsman P. · News Physiol Sci. · 2000 · 15 · 72
25. 10.1016/j.metabol.2007.07.02010.1016/j.metabol.2007.07.020 ↗
26. 10.1007/s00125-003-1087-710.1007/s00125-003-1087-7 ↗
27. 10.1111/j.1525-1594.1996.tb04587.x10.1111/j.1525-1594.1996.tb04587.x ↗
28. 10.1039/c3lc50601k10.1039/c3lc50601k ↗
29. 10.1016/S0956-5663(00)00088-910.1016/S0956-5663(00)00088-9 ↗
30. 10.1016/j.memsci.2008.09.03910.1016/j.memsci.2008.09.039 ↗
31. 10.1677/joe.0.128002710.1677/joe.0.1280027 ↗
32. 10.1007/s12575-009-9021-010.1007/s12575-009-9021-0 ↗
33. 10.2337/diabetes.54.suppl_2.S9710.2337/diabetes.54.suppl_2.S97 ↗
34. 10.2337/diabetes.49.9.146810.2337/diabetes.49.9.1468 ↗
35. 10.1002/jbm.a.3213410.1002/jbm.a.32134 ↗
36. Fissell W. H. · J. Am. Soc. Nephrol. · 2002 · 13 · 602a
37. 10.1097/01.mat.0000205228.30516.9c10.1097/01.mat.0000205228.30516.9c ↗
38. 10.1021/la000609d10.1021/la000609d ↗
39. 10.2337/db15-079210.2337/db15-0792 ↗
40. 10.1097/TP.0b013e3181d54bce10.1097/TP.0b013e3181d54bce ↗